Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Michael Bech Jensen"'
Autor:
Anna B. Schönwandt, Michael Bech Jensen, Preben Þstfeldt, Tina Norsell, Hanne Nedergaard, Per B. Þstergaard, Jens Bjerre, Britt Petersson
Publikováno v:
Clinical Therapeutics. 30:917-923
Background: Recombinant activated factor VIIa (rFVIIa) is indicated for on-demand treatment of bleeding and the prevention and treatment of surgical bleeding in patients with hemophilia A or B who have antibodies to coagulation factors VIII or IX. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::904200e3986bbdbe1648698b9ee0b2a2
https://doi.org/10.1016/j.clinthera.2008.05.001
https://doi.org/10.1016/j.clinthera.2008.05.001
Autor:
Michael Bech Jensen, Jens Bjerre, Tina Norsell, Hanne Nedergaard, Pernille Theil Jensen, P. Østergaard, Susanne Vestergaard, Morten Wagner Kristiansen
Publikováno v:
Clinical therapeutics. 30(7)
Recombinant activated factor VII (rFVIIa) is indicated to treat bleeding episodes or prevent bleeding related to surgery in patients with hemophilia A or B who have antibodies to coagulation factors VIII or IX. The first-generation rFVIIa formulation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a97b7480cee68ce69f14ba77d7af5fb5
https://pubmed.ncbi.nlm.nih.gov/18691990
https://pubmed.ncbi.nlm.nih.gov/18691990